We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+35.5%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$614M
AUM Growth
+$229M
Cap. Flow
+$94.5M
Cap. Flow %
15.38%
Top 10 Hldgs %
48.42%
Holding
129
New
38
Increased
24
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$12.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.48M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.95M
4
AZN icon
AstraZeneca
AZN
+$6.54M
5
NICE icon
Nice
NICE
+$5.73M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$50.1M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$6.5M
4
GSK icon
GSK
GSK
+$6.39M
5
AGN
Allergan plc
AGN
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 57.48%
2 Technology 4.42%
3 Communication Services 1.38%
4 Industrials 1.09%
5 Consumer Discretionary 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
101
UnitedHealth
UNH
$376B
$238K 0.04%
+1,700
New +$238K
MHK icon
102
Mohawk Industries
MHK
$7.5B
$220K 0.04%
+1,100
New +$226K
CABO icon
103
Cable One
CABO
$227M
$216K 0.04%
+370
New +$200K
LOW icon
104
Lowe's Companies
LOW
$117B
$212K 0.03%
+2,940
New +$229K
HSIC icon
105
Henry Schein
HSIC
$9.77B
$163K 0.03%
+2,550
New +$169K
ELLO icon
106
Ellomay Capital Ltd
ELLO
$270M
$51K 0.01%
5,653
– –
ABEO icon
107
Abeona Therapeutics
ABEO
$366M
– –
-5,524
Closed -$326K
ACHC icon
108
CALL
Acadia Healthcare
ACHC
$2.76B
– –
-1,500
Closed -$4.87M
ALNY icon
109
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-600
Closed -$3.33M
BHC icon
110
Bausch Health
BHC
$2.58B
– –
-68,500
Closed -$1.38M
BIIB icon
111
PUT
Biogen
BIIB
$30B
– –
-250
Closed -$6.05M
BLUE
112
DELISTED
bluebird bio
BLUE
– –
-3,088
Closed -$1.73M
CYTK icon
113
Cytokinetics
CYTK
$10.5B
– –
-32,069
Closed -$304K
DARE icon
114
Dare Bioscience
DARE
$18.3M
– –
-3,750
Closed -$954K
GSK icon
115
GSK
GSK
$104B
– –
-318,630
Closed -$6.39M
PTCT icon
116
PTC Therapeutics
PTCT
$5.68B
– –
-174,461
Closed -$1.23M
RARE icon
117
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-105,000
Closed -$5.14M
SAGE
118
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-1,000
Closed -$3.01M
SCYX icon
119
SCYNEXIS
SCYX
$48.1M
– –
-1,606
Closed -$279K
VRTX icon
120
Vertex Pharmaceuticals
VRTX
$121B
– –
-57,600
Closed -$4.96M
CLVS
121
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-200,000
Closed -$2.74M
TMX
122
DELISTED
Terminix Global Holdings, Inc.
TMX
– –
-41,431
Closed -$1.1M
RDUS
123
DELISTED
Radius Health, Inc.
RDUS
– –
-90,000
Closed -$3.31M
GWPH
124
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-310
Closed -$2.84M
BCOM
125
DELISTED
B Communications Ltd
BCOM
– –
-148,861
Closed -$3.56M
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sphera Funds Management held 129 positions worth $614M, up 59% from $385M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sphera Funds Management deployed $94.5M of net new capital in Q3 2016, opening 38 new positions and adding to 24 existing holdings. Its largest new stake was Sarepta Therapeutics: 263,047 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 77% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Shire pic, an estimated $50.1M trimmed.

  • Sphera Funds Management's largest Q3 2016 buy was Sarepta Therapeutics: 263,047 shares worth $16.2M.
  • Sphera Funds Management added most to Merck in Q3 2016, an estimated $12.3M increase.
  • Sphera Funds Management's biggest Q3 2016 reduction was Shire pic, cutting an estimated $50.1M.
  • Sphera Funds Management fully exited GSK in Q3 2016, selling an estimated $6.39M.
  • Sphera Funds Management's ten largest holdings make up 48% of its $614M portfolio in Q3 2016.
  • Sphera Funds Management opened 38 new positions and closed 23 in Q3 2016.
  • Sphera Funds Management's portfolio value rose 59% quarter-over-quarter to $614M.

Based on Sphera Funds Management's 13F filing for Q3 2016, filed 14 Nov 2016.